{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', '8.3 Pharmacogenetics', 'Not applicable', 'Level 2 heading added to the protocol', 'This level 2 heading', 'was added to', 'streamline the', 'genotyping portion', 'of the protocol', '8.3.1 CYP2D6 Genotype-Genotyping/Pharmacogenetics', 'At the screening visit, a blood sample', 'At the screening visit, a blood sample', 'This section was', '(5 to 6 mL) will be obtained for', '(5 to 6 mL) will be obtained for', 'updated to include', 'analysis of CYP2D6 genotype. The', 'analysis of CYP2D6 genotype. The', 'greater clarity on the', \"patient's genotype for CYP2D6 will\", \"patient's genotype for CYP2D6 will\", 'process of CYP2D6', 'remain blinded during the conduct of', 'remain blinded during the conduct of', 'genotyping and the', 'the study. If the patient elects this', 'the study. If the patient elects this', 'genetic samples that', 'option on the optional informed', 'option on the optional informed', 'may be obtained', 'consent, the remaining sample will be', 'consent, the remaining sample will be', 'from patients.', 'stored for exploratory', 'stored for exploratory', 'pharmacogenetics (PGx) evaluation.', 'pharmacogenetics (PGx) evaluation.', 'This PGx assessment will investigate', 'This PGx assessment will investigate', \"the relationship between subjects'\", \"the relationship between subjects'\", 'genetic variability and study outcomes.', 'genetic variability and study outcomes.', 'Candidate genes included in this', 'Candidate genes included in this', 'assessment may be related to, or', 'assessment may be related to, or', 'hypothesized to be related to', 'hypothesized to be related to', 'pharmacokinetics, safety features, drug', 'pharmacokinetics, safety features, drug', 'mechanism of action, Tourette', 'mechanism of action, Tourette', 'syndrome, or related diseases. The final', 'syndrome, or related diseases. The final', 'list of genes to be evaluated will be', 'list of genes to be evaluated will be', 'determined at the time of analysis to be', 'determined at the time of analysis to be', 'able to account for the most current', 'able to account for the most current', 'research.', 'research.', '9.5.4.3 Key Secondary Efficacy Analyses', 'A hierarchical (fixed-sequence) testing', 'A hierarchical (fixed-sequence) testing', 'This section was', 'approach will be used for the analysis', 'approach will be used for the analysis', 'updated to present', 'of the primary and key secondary', 'of the primary and key secondary', 'the changes in the', 'endpoints to maintain the experiment-', 'endpoints to maintain the experiment-', 'key secondary', 'wise type I error rate of 5%. If an', 'wise type I error rate of 5%. If an', 'efficacy endpoints', 'endpoint is not statistically significant,', 'endpoint is not statistically significant,', 'and analyses (ie, the', 'confirmatory hypothesis testing will', 'confirmatory hypothesis testing will', 'addition of TS-PGII,', 'not be carried out on the remaining', 'not be carried out on the remaining', 'the removal of TS-', 'hypotheses, and remaining hypotheses', 'hypotheses, and remaining hypotheses', 'PGIS, and the use of', 'will be considered exploratory rather', 'will be considered exploratory rather', 'the child and', 'than confirmatory. The change in the', 'than confirmatory. The change in the', 'adolescent version of', 'TS CGI (1),', '(2), and C&A-', 'TS CGI (1) and C&A-GTS-QOL ADL', 'the GTS-QOL scale.)', 'GTS-QOL physical/ADL subscale (3)', 'subscale (3) scores from baseline to', 'scores from baseline to week 12 will be', 'week 12 will be summarized and', '161']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'summarized and analyzed in the same', 'analyzed in the same fashion as the', 'fashion as the primary analysis, with', 'primary analysis, with the exception', 'the exception that the baseline value of', 'that the baseline value of the given', 'the given endpoint will be included as', 'endpoint will be included as the', 'the covariate. TS PGII (2) will be', 'covariate. TS PGII (2) will be analyzed', 'analyzed using a Cochran-Mantel-', 'using a Cochran-Mantel-Haenszel row', 'Haenszel row mean score test with a', 'mean score test with a modified ridit', 'modified ridit scoring that controls for', 'scoring that controls for age group.', 'age group.', '9.5.4.4 Exploratory Analyses', 'This section was', 'updated to present', 'the changes in the', 'exploratory', 'endpoints and', 'analyses', ':', '162']\n\n###\n\n", "completion": "END"}